Volume | 417,581 |
|
|||||
News | - | ||||||
Day High | 1.01 | Low High |
|||||
Day Low | 0.93 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cara Therapeutics Inc | CARA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.01 | 0.93 | 1.01 | 0.9669 | 0.9585 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,326 | 417,581 | $ 0.9813939 | $ 409,811 | - | 0.90 - 12.81 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:58:26 | 34 | $ 0.97 | USD |
Cara Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
52.85M | 54.48M | - | 41.87M | -85.47M | -1.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cara Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CARA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.00 | 1.02 | 0.90 | 0.9583208 | 487,487 | -0.042 | -4.2% |
1 Month | 1.22 | 1.40 | 0.90 | 1.09 | 488,634 | -0.262 | -21.48% |
3 Months | 2.13 | 2.48 | 0.90 | 1.55 | 588,756 | -1.17 | -55.02% |
6 Months | 3.48 | 4.45 | 0.90 | 2.68 | 977,775 | -2.52 | -72.47% |
1 Year | 11.11 | 12.81 | 0.90 | 4.31 | 778,280 | -10.15 | -91.38% |
3 Years | 14.95 | 29.6473 | 0.90 | 11.17 | 754,333 | -13.99 | -93.59% |
5 Years | 18.38 | 29.6473 | 0.90 | 13.51 | 692,549 | -17.42 | -94.79% |
Cara Therapeutics Description
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. |